Back to Awarded Treatment Trials
Awarded Trial: 01T-420
Grant ID
01T-420
Illness
Schizophrenia
Primary Drug/Intervention
Celecoxib
Primary Dosage
400 mg
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Dolnak
Sample Size
35
Duration of Study Period for Each Subject
8 weeks
Outcome Measurements
PANSS, Calgary Depression, extra-pyramidal side effects and akathesia or quality of life scales
Results
Thirty-five subjects were randomized to receive celecoxib 400 mg given adjunctively to antipsychotics or placebo for eight weeks. No differences were found between groups on PANSS, Calgary Depression, extra-pyramidal side effect or quality of life scales. Soluble interleukin-2 receptor levels did not predict response to the drug.
Publication
Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biological Psychiatry 57:1594-1596, 2005.
Link
http://www.ncbi.nlm.nih.gov/pubmed/15953498
PI Name
Doug Dolnak
Degree
MD
Center
Department of Psychiatry
Institution
University of California
Address
8950 Villa la Jolla Drive, C207
City or Town
La Jolla
State or Province
CA
Zip or Postal Code
92037
Country
USA
Email Address
ddolnak@ucsd.edu